Factors influencing postembolization syndrome in patients with hepatocellular carcinoma undergoing first transcatheter arterial chemoembolization

被引:17
|
作者
He, Jing-Jing [1 ]
Yin, Xi-Xi [1 ]
Wang, Ting [1 ]
Chen, Min-Ying [1 ]
Li, Xi-Long [1 ]
Yang, Xin-Jing [1 ]
Shao, Hong-Yan [1 ]
机构
[1] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Guangdong, Peoples R China
关键词
Hepatocellular carcinoma; postembolization syndrome; transcatheter arterial chemoembolization; HEPATIC TRANSARTERIAL CHEMOEMBOLIZATION; POST-EMBOLIZATION SYNDROME; RISK-FACTORS; MANAGEMENT; EFFICACY; CANCER; SAFETY; BEADS;
D O I
10.4103/jcrt.jcrt_132_21
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Context: Postembolization syndrome (PES) is the most common complication in patients with hepatocellular carcinoma (HCC) who had undergone transcatheter arterial chemoembolization (TACE). PES was defined as fever, nausea and/or vomiting, and abdominal pain and these symptoms develop within 1-3 days after TACE. However, few studies have explored the factors influencing PES in patients with TACE for the first time. Aims: We explored the factors influencing PES in patients with HCC undergoing TACE for the first time. Settings and Design: The present study was a hospital-based study conducted in the tertiary care hospital of Guangzhou with a retrospective study design. Subjects and Methods: In this single-center retrospective study, a total of 242 patients with HCC were included in the first TACE program between November 1, 2018 and November 31, 2019. Statistical Analysis Used: T-test and Chi-square test revealed the factors affecting the occurrence of PES. Correlation analysis (Spearman) explored the relationship between these factors and PES. Binary logistics analyzed the predictive factors of PES. Results: The probability of PES in patients with HCC undergoing TACE for the first time was 55.45%. Types of embolic agents (r = 0.296), types of microspheres (r = 0.510), number of microspheres (r = 0.130), maximum diameter of microspheres used (r = 0.429), type of drug (r = 0.406), and drug loading (r = 0.433) were positively correlated with PES (P < 0.05). Serum albumin was negatively correlated with PES (P = 0.008, r = -0.170). Binary logistic regression analysis revealed that drug loading microspheres (odds ratio [OR] = 0.075, 95% confidence interval [CI] = 0.031-0.180) and serum albumin (OR = 0.182, 95% CI = 0.068-0.487) were the protective factors influencing PES, while drug loading was the risk factor of PES (OR = 1.407, 95% CI = 1.144-1.173). Conclusions: Drug loading microspheres, serum albumin, and drug loading were the predictors of PES after the first TACE.
引用
收藏
页码:777 / 783
页数:7
相关论文
共 50 条
  • [21] TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION FOR HEPATOCELLULAR-CARCINOMA
    YANG, CF
    HO, YZ
    CHANG, JM
    CHIANG, RH
    LAI, KH
    LEE, SD
    TSAI, YT
    LUI, WY
    LIU, TJ
    CHEN, GH
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1989, 23 : S26 - S28
  • [22] Expression of angiogenic factors in hepatocellular carcinoma after transcatheter arterial chemoembolization
    Liao Xiaofeng
    Yi Jilin
    Li Xingrui
    Yang Zhifang
    Deng Wei
    Tian Geng
    Current Medical Science, 2003, 23 (3) : 280 - 282
  • [23] Expression of Angiogenic Factors in Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization
    廖晓锋
    易继林
    李兴睿
    杨志芳
    邓巍
    田耕
    华中科技大学学报(医学英德文版), 2003, (03) : 280 - 282
  • [24] Transcatheter arterial chemoembolization in hepatocellular carcinoma - Reply
    Llovet, JM
    Castells, A
    Bruix, J
    HEPATOLOGY, 1998, 28 (05) : 1442 - 1443
  • [25] Hepatocellular carcinoma: treatment with transcatheter arterial chemoembolization
    Acunas, B
    Rozanes, I
    EUROPEAN JOURNAL OF RADIOLOGY, 1999, 32 (01) : 86 - 89
  • [26] TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION FOR HEPATOCELLULAR-CARCINOMA
    YANG, CF
    HO, YJ
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1992, 31 : S86 - S88
  • [27] Risk factors of death after transcatheter arterial chemoembolization for hepatocellular carcinoma
    Chung, Woo Jin
    Jeon, Sang Hoon
    Jang, Yong Seok
    Kang, Min Kyung
    Shin, Yo Sig
    Lee, Seung Hyun
    Jang, Byung Kuk
    Park, Kyung Sik
    Cho, Kwang Bum
    Hwang, Jae Seok
    Ahn, Sung Hun
    Kim, Young Hwan
    Choi, Jin Su
    Kwon, Jung Hyeok
    HEPATOLOGY, 2006, 44 (04) : 505A - 505A
  • [28] Efficacy of sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization
    Ikeda, Masafumi
    Mitsunaga, Shuichi
    Shimizu, Satoshi
    Ohno, Izumi
    Takahashi, Hideaki
    Okuyama, Hiroyuki
    Kuwahara, Akiko
    Kondo, Shunsuke
    Morizane, Chigusa
    Ueno, Hideki
    Satake, Mitsuo
    Arai, Yasuaki
    Okusaka, Takuji
    JOURNAL OF GASTROENTEROLOGY, 2014, 49 (05) : 932 - 940
  • [29] Carboplatin as an anticancer agent for transcatheter arterial chemoembolization in patients with hepatocellular carcinoma
    Yamashita, F
    Tanaka, M
    Andou, E
    Yutani, S
    Kato, O
    Tanikawa, K
    ONCOLOGY, 1997, 54 (01) : 28 - 33
  • [30] Efficacy of sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization
    Masafumi Ikeda
    Shuichi Mitsunaga
    Satoshi Shimizu
    Izumi Ohno
    Hideaki Takahashi
    Hiroyuki Okuyama
    Akiko Kuwahara
    Shunsuke Kondo
    Chigusa Morizane
    Hideki Ueno
    Mitsuo Satake
    Yasuaki Arai
    Takuji Okusaka
    Journal of Gastroenterology, 2014, 49 : 932 - 940